First GLP-1 pill for weight loss, diabetes shows success in late-phase trial

Injectables for type 2 diabetes and weight loss could soon be a thing of the past.
Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered as a once-daily oral pill.
The ACHIEVE-1 trial evaluated the efficacy of Orforglipron compared to placebo in adults with type 2 diabetes and "inadequate glycemic control with diet and exercise alone."
Fake Ozempic Drugs Found In Us Drug Supply, Fda Warns
The results showed lowered A1C (blood sugar) in patients by an average of 1.3% to 1.6% across doses, according to a press release.
More than 65% of participants taking the highest dose of the drug scored an A1C less than or equal to 6.5%, which is below the defined threshold for diabetes, according to the American Diabetes Association.
Read On The Fox News App
Click Here To Sign Up For Our Health Newsletter
Trial participants also saw reduced weight by an average of 16 pounds, or 7.9%, at the highest dose.
Participants had not reached a weight plateau when the study ended, which suggests there was still weight to be lost, according to the researchers.
The trial also found that the overall safety and tolerability of the drug was consistent with the classic injectable GLP-1s, like Ozempic, Wegovy, Mounjaro and Zepbound.
If Orforglipron achieves approval by the U.S. Food and Drug Administration, Eli Lilly projected its confidence in launching the drug "worldwide without supply constraints."
For more Health articles, visit www.foxnews.com/health
"This would further Lilly's mission to reduce chronic diseases like type 2 diabetes, which is expected to impact an estimated 760 million adults by 2050," the pharmaceutical company wrote in its announcement.
David A. Ricks, Eli Lilly chair and CEO, commented in a statement, "We are pleased to see that our latest incretin medicine meets our expectations for safety and tolerability, glucose control and weight loss, and we look forward to additional data readouts later this year."
"As a convenient once-daily pill, Orforglipron may provide a new option and, if approved, could be readily manufactured and launched at scale for use by people around the world."
Eli Lilly intends to submit Orforglipron for weight management to global regulatory agencies by the end of 2025, as well as for type 2 diabetes treatment in 2026, according to the company.Original article source: First GLP-1 pill for weight loss, diabetes shows success in late-phase trial

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Insider

an hour ago

• Business Insider

BioAge Labs announces it will present new preclinical data on APJ agonism

BioAge Labs (BIOA) announced that it will present new preclinical data supporting apelin receptor, APJ, agonism for the treatment of diabetic obesity and heart failure with preserved ejection fraction. The data will be presented at the American Diabetes Association's 85th Scientific Sessions, held June 20-23, 2025, in Chicago, Illinois. In their two presentations, the company will present data that demonstrated that in preclinical models of diabetic obesity and HFpEF, APJ agonist treatment had potential as monotherapy that could be enhanced in combination with incretin therapies. Enhanced glycemic control in diabetic obesity – Dr. Rubin's oral presentation will show that in mouse models of diabetic obesity, APJ agonist monotherapy reduced HbA1c to levels comparable to lean controls and improved glucose tolerance by 25%. Cardioprotective effects in HFpEF – Dr. Yan's poster will show that in a mouse model of obesity-associated heart failure, APJ agonist monotherapy reduced cardiac hypertrophy and suppressed markers of cardiac injury. Combination of APJ agonism with an incretin provided enhanced cardioprotective benefits and greater weight loss compared to either treatment alone. Confident Investing Starts Here:

Business Insider

4 hours ago

• Business Insider

Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Sarepta Therapeutics (SRPT) and Eli Lilly & Co (LLY)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insulet (PODD – Research Report), Sarepta Therapeutics (SRPT – Research Report) and Eli Lilly & Co (LLY – Research Report) with bullish sentiments. Confident Investing Starts Here: Insulet (PODD) In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Insulet. The company's shares closed last Friday at $303.15. According to Marcus is a 4-star analyst with an average return of 9.1% and a 52.8% success rate. Marcus covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Bausch + Lomb Corporation, and Inspire Medical Systems. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insulet with a $337.56 average price target, a 10.9% upside from current levels. In a report issued on June 16, Truist Financial also initiated coverage with a Buy rating on the stock with a $365.00 price target. See Insiders' Hot Stocks on TipRanks >> Sarepta Therapeutics (SRPT) In a report issued on June 20, Anupam Rama from J.P. Morgan maintained a Buy rating on Sarepta Therapeutics, with a price target of $30.00. The company's shares closed last Friday at $20.08. According to Rama has 0 stars on 0-5 stars ranking scale with an average return of -6.9% and a 37.7% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Ultragenyx Pharmaceutical, and Kiniksa Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sarepta Therapeutics with a $44.96 average price target, implying an 115.4% upside from current levels. In a report issued on June 5, Scotiabank also upgraded the stock to Buy with a $80.00 price target. Eli Lilly & Co (LLY) Bernstein analyst Courtney Breen maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $1100.00. The company's shares closed last Friday at $762.73. According to Breen is a 2-star analyst with an average return of 0.5% and a 33.3% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Gilead Sciences, and Merck & Company. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $999.57 average price target, implying a 27.2% upside from current levels. In a report issued on June 6, Bank of America Securities also maintained a Buy rating on the stock with a $1000.00 price target.

Yahoo

5 hours ago

• Yahoo

Mounjaro weight loss jab: All you need to know

GPs in England will be able to prescribe weight loss jabs for the first time on the NHS on Monday, as the health service begins its mass rollout. Some 220,000 people with the 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly, through the NHS over the next three years. Here the PA news agency takes a look at the drug and the rollout. – How does tirzepatide work? Tirzepatide, or Mounjaro, is an antidiabetic drug which lowers blood sugar levels and slows down how quickly food is digested. It makes you feel fuller for longer and therefore less hungry. If the jab is recommended by a healthcare professional, those using it will need to eat a balanced, reduced-calorie diet and to exercise regularly while taking it, according to the NHS website. – Who might be eligible for the drug? In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of more than 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. It was previously only accessible to patients through a special weight loss service, to severely obese people who also suffer from a range of other health problems. Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. – How would it be administered? The drug is usually delivered through a self-administered weekly injection which a doctor or nurse will show patients how to use, the NHS website says. – Who cannot take tirzepatide? Mounjaro is not recommended for those who are pregnant or planning to get pregnant, breastfeeding or have certain health conditions, according to the NHS. For those taking the contraceptive pill and using tirzepatide, the NHS recommends using an additional method of contraception, such as a condom, for the first four weeks of treatment and for four weeks after each dose increase as the contraceptive pill may not be absorbed by the body during this time. – What are the potential side effects? Potential side effects of tirzepatide include nausea, vomiting, diarrhoea and constipation, according to the National Institute for Health and Care Excellence.